GlassScriptPhysician profile
Amer Rassam
NPI 1952370769
$10,982.13
in general payments reported to CMS, 2019-2025
51 companies · $4,947 in 2025
The $4,947 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $166 · 2021: $427 · 2022: $751 · 2023: $1,467 · 2024: $2,779 · 2025: $4,947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,004 · Travel and Lodging: $3,622 · Education: $514 · Gift: $52.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,003.54 |
| Travel and Lodging | $3,622.19 |
| Education | $514.20 |
| Gift | $52.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Onmark, INC. | $3,999.49 | 2025 | |
| US Oncology Corporate, INC. | $1,515.95 | 2024 | |
| Novartis Pharmaceuticals Corporation | $715.19 | 2019-2025 | |
| Pfizer INC. | $397.01 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $354.04 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $334.09 | 2022-2025 | Xospata, Vyloy |
| Celgene Corporation | $307.80 | 2022-2025 | Reblozyl, Opdivo, Opdualag |
| Mckesson Specialty Care Distribution, LLC | $256.00 | 2019 | |
| Eisai INC. | $216.97 | 2022-2025 | |
| Genzyme Corporation | $195.23 | 2022-2025 | |
| Lilly USA, LLC | $167.99 | 2019-2025 | Jaypirca, Retevmo, Verzenio |
| Incyte Corporation | $160.42 | 2023-2025 | Jakafi |
| Janssen Biotech, INC. | $158.00 | 2020-2025 | Darzalex, Talvey, Erleada |
| Takeda Pharmaceuticals U.S.A., INC. | $147.40 | 2023-2025 | Fruzaqla, Iclusig |
| E.R. Squibb & Sons, L.L.C. | $144.75 | 2019-2025 | Opdivo, Camzyos |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $134.81 | 2022-2025 | Tukysa |
| Coherus Oncology, INC. | $133.89 | 2020-2024 | |
| Exelixis INC. | $129.62 | 2022-2025 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $127.78 | 2019-2024 | Tagrisso, Enhertu, Imfinzi |
| Amgen INC. | $109.13 | 2022-2023 | Kyprolis |
| Glaxosmithkline, LLC. | $106.11 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Sanofi-Aventis U.S. LLC | $99.95 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.62 | 2022-2024 | Gilotrif |
| Octapharma USA, INC. | $92.87 | 2022-2025 | Octagam Immune Globulin (Human) |
| Regeneron Healthcare Solutions, INC. | $85.11 | 2022-2023 | Libtayo |
| Janssen Scientific Affairs, LLC | $71.63 | 2022-2023 | Tecvayli, Darzalex |
| Genentech USA, INC. | $65.26 | 2023-2024 | Polivy, Venclexta, Gazyva |
| Daiichi Sankyo INC. | $63.59 | 2020-2024 | Enhertu |
| Gilead Sciences, INC. | $51.17 | 2021-2023 | |
| Novocure INC. | $45.75 | 2024 | Optune |
| Tempus Ai, INC | $40.55 | 2024-2025 | Xt Cdx |
| Alexion Pharmaceuticals, INC. | $35.51 | 2019-2022 | |
| Pharmacosmos Therapeutics INC. | $30.41 | 2023-2024 | Monoferric |
| Jazz Pharmaceuticals INC. | $28.99 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $28.93 | 2023-2024 | Truxima |
| Csl Behring | $26.35 | 2025 | Hizentra |
| Stemline Therapeutics INC. | $25.73 | 2025 | Orserdu |
| Array Biopharma INC | $24.63 | 2024 | Braftovi, Lorbrena, Mektovi |
| Puma Biotechnology, INC. | $24.00 | 2025 | |
| Kyowa Kirin, INC. | $23.19 | 2023 | Poteligeo |
| Fennec Pharmaceuticals, INC. | $22.76 | 2025 | Fyarro |
| Caris Mpi, INC. | $22.02 | 2025 | Mi Cancer Seek |
| Myriad Genetic Laboratories, INC. | $21.73 | 2023 | Myrisk |
| Servier Pharmaceuticals LLC | $20.67 | 2024 | |
| Emd Serono, INC. | $20.46 | 2025 | |
| Beone Medicines USA, INC. | $18.78 | 2025 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $18.64 | 2022-2024 | Tavalisse, Rezlidhia |
| Taiho Oncology, INC. | $17.37 | 2023 | |
| G1 Therapeutics, INC. | $16.58 | 2022 | |
| Karyopharm Therapeutics INC. | $15.25 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $14.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amer Rassam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.